By John Q. Hosedrinker 
Research from King’s College London reveals benralizumab, an injectable drug already used for severe cases, as the first new asthma attack treatment in 50 years. Targeting eosinophils, a type of white blood cell contributing to lung inflammation, the therapy significantly reduced treatment failure rates compared to steroids (45% vs. 74%) in a 158-person trial. This new approach offers improved symptoms, quality of life, and reduced hospitalizations, potentially impacting the two million asthma attacks annually in the UK. While further large-scale trials are needed, the findings suggest a potential “game-changer” in asthma and COPD treatment.
Read the original article here
The recent announcement of a “first new asthma attack treatment in 50 years” has sparked considerable debate, and rightly so. The headline, while attention-grabbing, is misleading. Several injectable treatments for eosinophilic asthma, a specific type of asthma, have been available for some time, including mepolizumab, dupilumab, and omalizumab. These monoclonal antibody injections offer a valuable alternative to traditional pills and inhalers, and some, like omalizumab, have been used for over a decade. The convenience of at-home administration further enhances their appeal.
The excitement surrounding the new treatment stems from its potential use during asthma exacerbations – acute attacks – rather than solely for preventative maintenance. Existing monoclonal antibodies primarily focus on disease management, preventing attacks rather than treating them actively during an episode. This new approach, while promising, represents a shift in how these drugs are utilized, not a revolutionary breakthrough in the treatment of asthma in general.
However, accessibility remains a significant hurdle. The high cost of these treatments, often exceeding thousands of dollars per dose, is a major concern. Many individuals express anxieties about affordability, highlighting the challenges faced by those without comprehensive insurance coverage, particularly in the United States. The complexities of the American healthcare system, and the potential loss of disability benefits when employment becomes a necessity to afford treatment, add another layer of difficulty. This disparity raises questions about equitable access to life-altering medications.
The financial burden is substantial, even with insurance. Significant co-pays are common, potentially placing the treatments out of reach for many. This financial barrier underscores the urgent need for improved accessibility and affordability of advanced asthma treatments. The discussion around the cost-effectiveness of these monoclonal antibodies compared to cheaper alternatives like steroids also highlights the complex economic considerations influencing treatment decisions.
Furthermore, the article’s central claim is inaccurate. The treatment isn’t entirely new; the medication itself has been around for several years, approved and used globally for managing eosinophilic asthma. The novel aspect is its investigation for use during acute asthma attacks. This distinction highlights the need for clearer communication and more nuanced understanding of the research findings.
While these injectable treatments represent significant advancements, particularly for those with severe or poorly controlled asthma, their role remains specialized. Many individuals manage their asthma effectively with inhalers and other less expensive treatments. The decision to pursue these expensive treatments requires careful evaluation of individual needs and cost-benefit considerations. The claim that it benefits a “minuscule amount of people” is misleading; while not everyone needs this type of treatment, a substantial number of people with severe asthma will benefit greatly. For those with severe asthma, these treatments can be truly life-changing, improving quality of life and reducing hospitalizations. This point of view makes the cost and access issues all the more critical.
The discussion reflects diverse perspectives, from individuals with personal experiences of managing asthma to healthcare professionals offering insights into the complexities of treatment and access. The perspectives of those without sufficient insurance, and the systemic obstacles to accessing essential medication, should not be overlooked. Ultimately, the conversation underscores the need for continued research, greater affordability, and improved access to advanced asthma treatments to ensure equitable healthcare for all.